Frontage has announced completion of its Pennsylvania site expansion to boost its offering of bioanalytical services for late-stage cell and gene therapies developers.
Following an inspection at its Ireland site, Almac received compliance certification for its Almac Adapt Just in Time’ clinical packaging and labelling manufacturing services.
Antibody-focused service providers merge their offerings to create a ‘seamless workflow’ on antibody-drug conjugates to help save developers’ time and costs.
Funding from Gamma supports the development of Univercells’ biomanufacturing platform and bioreactors, with the latter looking to expand into the fast-growing gene therapy segment.
Vineti’s latest financing round sees Novartis and Gilead join forces to invest in technology platform that enables scale-up of CAR Ts and allogeneic cell therapies.
